Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9026 |
MEISi-2
Benzoic acid, 4-hydroxy-, 2-[(Z)-(2-oxo-1(2H)-naphthalenylidene)methyl]hydrazide |
Others | Others |
MEISi-2 是 MEIS(造血干细胞自我更新的关键调控因子)选择性抑制剂。它可用于心脏损伤、造血问题、骨髓移植和癌症的研究。 | |||
T69793 |
VEL-0230
|
||
VEL-0230, also known as NC-2300, is a potent cathespin K inhibitor. VEL-0230 has dual-acting properties that both stimulates bone formation and inhibits loss. VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Velcura Therapeutics is currently being developed by Velcura Therapeutics. Given VEL- 0230's promotion of bone formation, inhibition o... |